Diazoxide
Diazoxide, Proglycem (diazoxide) is a small molecule pharmaceutical. Diazoxide was first approved as Hyperstat on 1982-01-01. It is used to treat hypoglycemia and malignant hypertension in the USA. It is known to target ATP-sensitive inward rectifier potassium channel 8 and ATP-sensitive inward rectifier potassium channel 11.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Diazoxide, Proglycem (discontinued: Diazoxide, Hyperstat, Proglycem)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypoglycemia | HP_0001943 | D007003 | E16.2 |
| malignant hypertension | EFO_1001031 | D006974 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C02: Antihypertensives
— C02D: Arteriolar smooth muscle, agents acting on
— C02DA: Thiazide derivatives acting on arteriolar smooth muscle
— C02DA01: Diazoxide
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AH: Drugs for treatment of hypoglycemia
— V03AH01: Diazoxide
HCPCS
Code | Description |
|---|---|
| J1730 | Injection, diazoxide, up to 300 mg |
Clinical
Clinical Trials
35 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | 3 | 1 | 4 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 3 | — | 1 | — | 4 |
| Glucose metabolism disorders | D044882 | — | — | — | 3 | — | 1 | — | 4 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | 3 | — | 1 | — | 4 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | — | 1 | 1 | 3 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | — | 1 | 1 | 2 | — | 3 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | — | — | — | 1 | — | 1 |
| Pure autonomic failure | D054970 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | 1 | 1 | 4 | — | 1 | 6 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 4 | 1 | — | — | 6 |
| Hypertriglyceridemia | D015228 | EFO_0004211 | — | 3 | 2 | 1 | — | — | 6 |
| Prader-willi syndrome | D011218 | Orphanet_739 | Q87.11 | 1 | 2 | 4 | — | — | 6 |
| Craniopharyngioma | D003397 | — | — | — | 1 | 1 | — | — | 2 |
| Adamantinoma | D050398 | — | — | — | 1 | 1 | — | — | 2 |
| Pregnancy in diabetics | D011254 | — | O24.91 | — | 1 | 1 | — | — | 1 |
| Newborn infant diseases | D007232 | — | — | — | 1 | 1 | — | — | 1 |
| Pituitary diseases | D010900 | — | E23.7 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperinsulinism | D006946 | HP_0000842 | E16.1 | 2 | 1 | — | — | — | 3 |
| Dyslipidemias | D050171 | HP_0003119 | — | — | 1 | — | — | — | 1 |
| Depression | D003863 | — | F33.9 | 1 | 1 | — | — | — | 1 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial stunning | D017682 | — | — | 2 | — | — | — | — | 2 |
| Insulin resistance | D007333 | HP_0000855 | — | 2 | — | — | — | — | 2 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | 1 | — | — | — | — | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | — | — | — | — | 1 |
| Fatty liver | D005234 | EFO_0003934 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | — | — | 2 | 2 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | — | — | 1 | 1 |
| Reperfusion injury | D015427 | — | — | — | — | — | — | 1 | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | — | — | 1 | 1 |
| Fever | D005334 | HP_0001945 | R50.9 | — | — | — | — | 1 | 1 |
| Ovarian epithelial carcinoma | D000077216 | — | — | — | — | — | — | 1 | 1 |
| Hyperthermia | D000084462 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Diazoxide |
| INN | diazoxide |
| Description | Diazoxide is a benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies. It has a role as an antihypertensive agent, a sodium channel blocker, a vasodilator agent, a K-ATP channel agonist, a beta-adrenergic agonist, a cardiotonic drug, a bronchodilator agent, a sympathomimetic agent and a diuretic. It is a benzothiadiazine, a sulfone and an organochlorine compound. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |
Identifiers
| PDB | — |
| CAS-ID | 364-98-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL181 |
| ChEBI ID | 4495 |
| PubChem CID | 3019 |
| DrugBank | DB01119 |
| UNII ID | O5CB12L4FN (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
NAMPT
NAMPT
Organism
Homo sapiens
Gene name
NAMPT
Gene synonyms
PBEF, PBEF1
NCBI Gene ID
Protein name
nicotinamide phosphoribosyltransferase
Protein synonyms
NAmPRTase, Pre-B cell-enhancing factor, Pre-B-cell colony-enhancing factor 1, Visfatin
Uniprot ID
Mouse ortholog
Nampt (59027)
nicotinamide phosphoribosyltransferase (Q9JKM0)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Diazoxide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,407 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
540 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use